This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905-05 is to learn more about the study drug GS-3242 in PWH.
This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905-05 is to learn more about the study drug GS-3242 in PWH.
Study of GS-3242 in Participants With HIV-1
-
Quest Clinical Research,Substudy-05, San Francisco, California, United States, 94115
Washington Health Institute,Substudy-05, Washington, District of Columbia, United States, 20017
Midland Florida Clinical Research Center, LLC,Substudy-05, DeLand, Florida, United States, 32720
Midway Immunology & Research Center, LLC, Fort Pierce, Florida, United States, 34982
BLISS Health,Substudy-05, Orlando, Florida, United States, 32803
Orlando Immunology Center, PA,Substudy-05, Orlando, Florida, United States, 32803
Triple O Research Institute, P.A.,Substudy-05, West Palm Beach, Florida, United States, 33407
Chatham County Health Department,Substudy-05, Savannah, Georgia, United States, 31401
Central Texas Clinical Research,Substudy-05, Austin, Texas, United States, 78705
Prism Health North Texas,Substudy-05, Dallas, Texas, United States, 75208
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 65 Years
ALL
No
Gilead Sciences,
Gilead Study Director, STUDY_DIRECTOR, Gilead Sciences
2027-02